CVS stock sentiment todayCVS Health Corporation
Sentiment verdict
Gossip first, financials second — NEUTRAL at 75% confidence.
Last updated · cached analysis, refreshes periodically
CVS
CVS Health CorporationA complex vertical integration play currently caught between Medicare Advantage headwinds and a deep-value valuation floor.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for CVS. Not financial advice.
Price · last 12 months
Gossip
The narrative is dominated by the 'break-up' rumors and pressure from activist investor Glenview Capital. Markets are weighing the struggles of the Aetna insurance segment against the steady cash flow of the pharmacy services business.
- ·Speculation on a potential business unit spin-off
- ·Medicare Advantage Star Rating downgrades affecting future reimbursement
- ·Recent leadership change with David Joyner taking the CEO helm
Financial
CVS boasts massive revenue scale but is suffering from significant margin compression in its Health Care Benefits segment. While the balance sheet is leveraged from the Oak Street and Signify acquisitions, cash flow remains robust enough to support its 2.8%+ dividend yield.
- ·P/E Ratio (Forward) ~9.5x - historically low
- ·Operating Margin compression due to rising medical loss ratios (MLR)
- ·High debt-to-equity (~0.72) following aggressive M&A strategy
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Hollow — insiders are stepping back and the register is short-horizon.
- ·Insiders sold a net $317.5M on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Increased regulatory scrutiny on PBM (Pharmacy Benefit Manager) practices
- ·Rising medical costs exceeding premium increases in the Aetna division
- ·Execution risk regarding the transition to a 'value-based care' model
Peer temperature
How direct competitors stack up against CVS right now.
- HOTUNHUnitedHealth Group
HOTTER — Superior operational execution and diversified Optum health services provide much higher margins and growth stability.
See full analysis → - COLDWBAWalgreens Boots Alliance
COLDER — Lacks the integrated insurance arm of CVS and is struggling with significant debt, store closures, and a dividend cut.
See full analysis → - NEUTRALELVElevance Health
NEUTRAL — Similarly exposed to Medicare Advantage volatility but maintains a tighter focus on managed care without the retail pharmacy overhead.
See full analysis →
- CVS-2.4%
- UNH-3.8%
- WBA—
- ELV+4.2%
Analyst price target
Consensus average of 21 analysts · median 113.00
Source: StockAnalysis.com · updated 2026-09-04
AI-generated analysis for informational purposes only. Not financial advice.